US/UK/Canada

Share

Quotes

The goal is to attract a licensing partner after completing phase I/II in order to continue the development. An alternative scenario is to find a partner before entering clinical studies, based on a precise development plan
Suzanne Kilany, CRD Aptahem
It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects
Luiza Jedlina, CSO Aptahem
Aptahem is currently focusing on sepsis, but there is possibility for potentially expanding the indication. At present, no such decision has been made, but we are not ruling it out
Mikael Lindstam, CEO Aptahem
Pick a time period -
Tags ( Active)

Aptahem receives patent protection in China for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection in China for patent family 2 from the Chinese Patent Office.With the approval in China of patent application 2018800643106, the protection of the company’s drug candidate Apta-1 within patent family 2 in China, Chinese Patent No. 111386121, is valid until the end of 2038. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the

Aptahem receives Notice of Allowance in China for patent family 2

Aptahem AB (publ) announces today that the company has received a Notice of Allowance in China of the patent application no 2018800643106 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038. CEO Mikael Lindstam comments: ”The fact that we have now received notification that

Aptahem receives patent protection in South Korea for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection (Notice of Patent Grant) in South Korea for the patent application no 10-2020-7007266 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.With the approval in South Korea of patent application 10-2020-7007266, the protection of the company’s drug candidate Apta-1 within patent family 2 in South Korea is valid until the end of 2038. CEO Mikael Lindstam comments “I am pleased to announce that one of the few remaining patent applications has now been

Aptahem receives Notice of Allowance in Israel for patent family 2

Aptahem AB (publ) announces today that the company has received a Notice of Allowance in Israel of the patent application no 273759 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038. CEO Mikael Lindstam comments: ”I am very pleased to receive the news that yet another

Aptahem’s patent family 2 in Europe has been finalized by validation in the 11 countries where applied

Aptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been published with patent number 3691655.With these validations of the approved patent application in Europe, the company’s drug candidate Apta-1 is now protected within patent family 2 in the following countries: Sweden, Great Britain, Germany, France, Spain, Italy, The Netherlands, Austria, Poland, Turkey and Switzerland. The patent protection is valid until the end of 2038. CEO Mikael Lindstam

Aptahem receives Turkish patent for the protection of patent family 2

Aptahem AB (publ) announces today that the Turkish patent office has approved the patent application as the first validated country in Europe. The patent was published with the patent number TR2021/013877 T4.The approval by the Turkish patent office provides protection for the company’s lead candidate Apta-1 within the patent family 2 in Turkey until 2037. The validation phase for the other specific countries where Aptahem has applied for patent protection is ongoing, with expected more approvals to come. CEO Mikael Lindstam comments: ”I am very pleased to receive the final approval

Aptahem receives patent protection in USA for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection in USA for patent family 2 from the United States Patent and Trademark Office (USPTO). The approval follows the previous preliminary approval from USPTO which was communicated on 30 June 2021.With USPTO’s approval of patent application 16/652,926, the protection of the company’s drug candidate Apta-1 within patent family 2 in the USA, U.S. Patent No. 11,110,115, is valid until the end of 2037. CEO Mikael Lindstam comments: ”I am very pleased to receive the final approval from USPTO, Issue Notification,

Aptahem receives European patent for the protection of patent family 2

Aptahem AB (publ) announces today that the European Patent Office (EPO) has approved the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The approval follows the previous provisional approval by the EPO announed on July 5, 2021.The approval by the EPO of patent EP 18783424.7 provides protection for the company’s lead candidate Apta-1 within the patent family 2 in Europe until 2037. Now will the so called validation phase start when the company will decide in which specific European countries to

Aptahem receives Intention to Grant from the European Patent Office for the protection of patent family 2

Aptahem AB (publ) announces today that the company has received information that the European Patent Office (EPO) has issued an Intention to Grant of the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The application covers the therapeutic protection of the company’s aptamer Apta-1 which is being developed as treatment for disease syndroms caused by inflammation, coagulation and/or organ failure.This application is part of the patent family 2 with Aptahem’s CSO Dr Luiza Jedlina as the inventor.

Aptahem receives Notice of Allowance from the US Patent Office for the protection of patent family 2

Aptahem AB (publ) announces today that the company has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance fo the US patent application 16/652,926 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The application covers the therapeutic protection of the company’s aptamer Apta-1 which is being developed as treatment for disease syndroms caused by inflammation, coagulation and/or organ failure.This application is part of the patent family 2 with Aptahem’s CSO Dr Luiza Jedlina

Aptahem receives patent approval in India for patent family 1

Aptahem AB (publ) announce today that the company has received patent approval in India for patent family 1, with patent application number 6250/DELNP/2010. The patent, with the patent number 353024, covers the protection of the company’s aptamer structures.The patent approval grants the company protection for Apta-1, Apta-2 and Apta-3 in India until 2029. Similar patents have previously been approved in Europe, USA, Canada and China. CEO Mikael Lindstam comments: “We are delighted to announce that we now have received patent approval in the last country, India, for our patent

Aptahem’s latest patent application is registered in several countries

Aptahem today informs that the company’s latest patent application has been registered in several countries and are subject to approval. The patent application, which is an international PCT application*, is a merger of two previous Europe applications and have now entered a so called country phase where the company has selected the most value increasing geographies. The patent application refers to Apta-1 and has the title ”A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties”.The patent application was submitted in 2017 after acheiving new,

Aptahems latest patent application is published

Aptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe applications with the priority date 3 October 2017. The patent application refers to Apta-1 and has the title ”A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties” which will give Aptahem the possibility to apply for patent protection in up to 150 countries within approximately one year’s time. The company currently evaluates the most value increasing

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe